scholarly journals Bladder Cancer versus Hemorrhagic Cystitis: A Case of Mistaken Identity in a 34-Year-Old Male Undergoing Therapy for Granulomatosis with Polyangiitis

2014 ◽  
Vol 4 (2) ◽  
pp. 120-125 ◽  
Author(s):  
Jonathan Amatruda ◽  
Kevin Dieckhaus ◽  
Poornima Hegde ◽  
John Taylor
Keyword(s):  
Bladder Cancer ◽  
Granulomatosis With Polyangiitis ◽  
Hemorrhagic Cystitis ◽  
Mistaken Identity

Bladder cancer in cystoscopically normal-appearing mucosa: a case of mistaken identity?

2010 ◽  
Vol 106 (10) ◽  
pp. 1499-1501 ◽  
Author(s):  
Harry W. Herr ◽  
Hikmat Al-Ahmadie ◽  
Guido Dalbagni ◽  
Victor E. Reuter
Keyword(s):  
Bladder Cancer ◽  
Mistaken Identity

scholarly journals MP10-09 INCIDENCE AND MORBIDITY OF RADIATION-INDUCED HEMORRHAGIC CYSTITIS IN PROSTATE AND BLADDER CANCER

2018 ◽  
Vol 199 (4S) ◽  
Author(s):  
Sarah Martin ◽  
Eglal Samir ◽  
Mohammed Azaiza ◽  
Evan Begun ◽  
Mazen Abdelhady
Keyword(s):  
Bladder Cancer ◽  
Hemorrhagic Cystitis ◽  
Radiation Induced

scholarly journals Rituximab—A Drug with Many Facets and Cures: A Treatment for Acute Refractory Hypoxemic Respiratory Failure Secondary to Severe Granulomatosis with Polyangiitis

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Braden Powers ◽  
Aditya Uppalapati ◽  
Sindhura Gogineni ◽  
Zafar Akram Jamkhana
Keyword(s):  
Respiratory Failure ◽  
Granulomatosis With Polyangiitis ◽  
Hemorrhagic Cystitis ◽  
Kidney Injury ◽  
Control Mode ◽  
Volume Control ◽  
Hypoxemic Respiratory Failure ◽  
Granulomatous Vasculitis ◽  
Life Threatening ◽  
Pressure Release Ventilation

Granulomatosis with Polyangiitis (GPA) is a rare systemic anti neutrophil cytoplasmic antibody (ANCA-) associated granulomatous vasculitis of the small and medium sized blood vessels. Diffuse alveolar hemorrhage (DAH) is a rare life-threatening complication of GPA. In our patient, cyclophosphamide was held secondary to complications of acute kidney injury, hematuria, and concern for a possible hemorrhagic cystitis. However, during the workup for hematuria the patient acutely developed respiratory failure and was found to have DAH. The patient was initially supported with mechanical ventilation volume control mode, steroids, and plasma exchange. With no improvement of oxygenation, the mode of ventilation was changed to airway pressure release ventilation (APRV) and the patient was started on rituximab. The patient clinically improved over the next few days, was able to be extubated, and was transferred out of the intensive care unit.

scholarly journals Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseases

2015 ◽  
Vol 42 (9) ◽  
pp. 1661-1666 ◽  
Author(s):  
Neslihan Yilmaz ◽  
Hakan Emmungil ◽  
Sercan Gucenmez ◽  
Gulsen Ozen ◽  
Fatih Yildiz ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Rheumatic Diseases ◽  
Hemorrhagic Cystitis ◽  
Cox Proportional Hazard Model ◽  
Proportional Hazard ◽  
Proportional Hazard Model ◽  
Duration Of Therapy ◽  
Cox Proportional Hazard ◽  
Patient Groups ◽  
Similar Incidence

Objective.To assess bladder toxicity of cyclophosphamide (CYC) and uroprotective effect of mesna in rheumatic diseases.Methods.Data of 1018 patients (725 women/293 men) treated with CYC were evaluated in this retrospective study. All of the following information was obtained: the cumulative CYC dose, route of CYC administration, duration of therapy, concomitant mesna usage, and hemorrhagic cystitis. Cox proportional hazard model was used for statistics.Results.We identified 17 patients (1.67%) with hemorrhagic cystitis and 2 patients (0.19%) with bladder cancer in 4224 patient-years. The median time for diagnosis to hemorrhagic cystitis was 10 months (4–48) and bladder cancer was 8 years (6–10.9). There were 583 patients (57.2%) who received mesna with intravenous CYC therapy. We observed similar incidence rate for hemorrhagic cystitis in both patient groups concomitantly treated with or without mesna [9/583 (1.5%) vs 8/425 (1.8%) respectively, p = 0.08]. Cumulative CYC dose (HR for 10-g increments 1.24, p < 0.001) was associated with hemorrhagic cystitis.Conclusion.Cumulative dose was the only risk factor for hemorrhagic cystitis in patients treated with CYC. No proof was obtained for the uroprotective effect of mesna in our cohort.

Sex and Racial Disparities in the Treatment and Outcomes of Muscle-invasive Bladder Cancer

Urology ◽  
2020 ◽  
Author(s):  
Jessica Marinaro ◽  
Alexander Zeymo ◽  
Jillian Egan ◽  
Filipe Carvalho ◽  
Ross Krasnow ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Racial Disparities ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

775: Cell Culture Proteome Identifies CXCL 1 as a Secreted Marker and Mediator for the Tumor Invasion of Bladder Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 260-260 ◽  
Author(s):  
Hiroaki Kawanishi ◽  
Yoshiyuki Matsui ◽  
Toshinari Yamasaki ◽  
Takeshi Takahashi ◽  
Hiroyuki Nishiyama ◽  
...  
Keyword(s):  
Cell Culture ◽  
Bladder Cancer ◽  
Tumor Invasion

774: Improvement of Anti-Angiogenic and Anti-Tumorigenic Efficacy of Thrombospondin-1 by PPAR┌ Ligands in Bladder Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 259-259
Author(s):  
Thomas Nelius ◽  
Hanua Huang ◽  
Stephanie Filleur ◽  
Steven C. Campbell ◽  
Werner de Riese ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Thrombospondin 1 ◽  
Ppar Ligands

769: Matrix Metalloproteinase Polymorphisms are associated with Bladder Cancer Invasiveness

2007 ◽  
Vol 177 (4S) ◽  
pp. 258-258
Author(s):  
A. Karim Kader ◽  
Jun Liu ◽  
Una Shao ◽  
Colin P.N. Dinney ◽  
Jie Lin ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Matrix Metalloproteinase ◽  
Cancer Invasiveness
Sign in / Sign up

Export Citation Format

Share Document